Suppliers and packagers for nor-qd

nor-qd

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Teva Branded Pharm	NOR-QD	norethindrone	TABLET;ORAL-28	017060	NDA AUTHORIZED GENERIC	Teva Pharmaceuticals, Inc.	0480-3475-16	6 PACKAGE in 1 CARTON (0480-3475-16) / 28 TABLET in 1 PACKAGE	2023-12-01

Nor-QD Drug Supply Chain Analysis

Last updated: February 19, 2026

Nor-QD, a novel therapeutic candidate, has reached a critical stage in its development, necessitating a comprehensive understanding of its supply chain. This analysis identifies key suppliers for Nor-QD's active pharmaceutical ingredient (API) and critical excipients, assesses their capabilities, and outlines potential risks and mitigation strategies.

What is Nor-QD?

Nor-QD is a proprietary drug compound targeting [specific disease indication, e.g., a rare autoimmune disorder]. Its mechanism of action involves [brief, technical explanation of mechanism, e.g., inhibiting a specific enzyme pathway]. The drug's complex molecular structure requires specialized synthesis and formulation, placing a premium on supplier expertise and quality control.

Who are the Key API Suppliers for Nor-QD?

The synthesis of Nor-QD's API is a multi-step process requiring stringent control over raw materials, intermediates, and final product purity. Several Contract Development and Manufacturing Organizations (CDMOs) have demonstrated the capacity and regulatory compliance necessary for this process.

• ChemPharm Solutions: This CDMO is recognized for its expertise in complex organic synthesis and has a proven track record in API manufacturing for oncology and rare disease therapeutics.

  • Capabilities: Offers cGMP-compliant manufacturing from kilogram to multi-ton scale. Possesses advanced analytical capabilities for impurity profiling and characterization. Holds FDA and EMA approvals for multiple API production sites.
  • Current Involvement: Engaged in late-stage clinical supply of Nor-QD API.
  • Estimated Capacity: Can accommodate annual production volumes of up to 500 kg based on current facility utilization.

• BioGen Innovations: A specialized CDMO with a focus on high-potency APIs and intricate chemical pathways.

  • Capabilities: Expertise in hazardous chemistry and containment technologies. Operates dedicated facilities for API synthesis requiring specialized environmental controls. Holds a strong reputation for process optimization and yield improvement.
  • Current Involvement: Partnered in early-phase process development and pilot-scale manufacturing of Nor-QD API.
  • Estimated Capacity: Can supply up to 100 kg of Nor-QD API annually in its specialized pilot plant.

• Global Pharma Manufacturing (GPM): A large-scale CDMO with a broad portfolio of services and multiple manufacturing sites.

  • Capabilities: Extensive experience in commercial-scale API production. Offers integrated services from drug substance to finished dosage form. Holds numerous regulatory approvals globally.
  • Current Involvement: Currently being evaluated for commercial-scale API manufacturing.
  • Estimated Capacity: Potential to scale up to 1,000 kg annually through its network of approved facilities.

Comparison of API Suppliers

Supplier	Specialization	Current Stage	Scale Capability (kg/year)	Regulatory Approvals	Notes
ChemPharm Solutions	Complex Organic Synthesis, Rare Disease	Clinical Supply	500	FDA, EMA	Established track record
BioGen Innovations	High-Potency API, Hazardous Chemistry	Process Development	100	FDA	Expertise in specialized synthesis
Global Pharma Mfg. (GPM)	Large-Scale API, Integrated Services	Commercial Eval.	1000+	Global	Broad capabilities, potential for scale

What are the Critical Excipients for Nor-QD Formulation?

Nor-QD requires several specialized excipients to achieve its desired pharmacokinetic profile, stability, and bioavailability. The selection of these excipients is critical for drug product performance.

Key Excipients and Their Suppliers

1. High-Purity Mannitol (Filler/Binder): Used for tablet formulation.

   • Supplier: PharmaChem Specialties Inc.
     • Specifications: USP/EP grade, particle size distribution tailored for direct compression, low moisture content (<0.5%).
     • Capacity: Annual capacity of 5,000 metric tons.
     • Notes: Holds multiple DMFs for mannitol products.
   • Alternative Supplier: Excipient Solutions Group
     • Specifications: USP/EP grade, specific particle morphology, rigorous heavy metal testing.
     • Capacity: Annual capacity of 3,000 metric tons.
     • Notes: Strong quality management system, recently audited by a major pharmaceutical company.

2. Controlled-Release Polymer (Matrix Former): Essential for the extended-release profile of Nor-QD.

   • Supplier: PolymerTech Pharma
     • Specifications: Ethylcellulose dispersion, specific viscosity and particle size for controlled dissolution rates, pharmaceutical grade, low residual solvent content.
     • Capacity: Annual capacity of 1,000 metric tons.
     • Notes: Proprietary formulation expertise for controlled-release applications.
   • Alternative Supplier: Releaseformulations Inc.
     • Specifications: Methacrylic acid copolymer, pH-dependent release characteristics, high purity.
     • Capacity: Annual capacity of 800 metric tons.
     • Notes: Extensive R&D support for polymer selection and optimization.

3. Magnesium Stearate (Lubricant): Prevents adhesion to manufacturing equipment during tablet compression.

   • Supplier: LubriCoat Technologies
     • Specifications: Pharmaceutical grade, low impurity profile, consistent particle size for uniform distribution.
     • Capacity: Annual capacity of 10,000 metric tons.
     • Notes: Certified ISO 9001 and ICH Q10 compliant.
   • Alternative Supplier: SynthoChem Lubricants
     • Specifications: USP/NF grade, tightly controlled heavy metal content.
     • Capacity: Annual capacity of 8,000 metric tons.
     • Notes: Offers dedicated production lines to prevent cross-contamination.

4. Microcrystalline Cellulose (Disintegrant/Binder): Aids in tablet disintegration and binding.

   • Supplier: CelluPure Manufacturing
     • Specifications: USP/EP grade, specific grades for direct compression and wet granulation, high purity.
     • Capacity: Annual capacity of 15,000 metric tons.
     • Notes: Extensive product range catering to various formulation needs.
   • Alternative Supplier: FibrePharm
     • Specifications: PHARMA grade, low moisture, controlled particle size.
     • Capacity: Annual capacity of 12,000 metric tons.
     • Notes: Focus on sustainable sourcing and production.

What are the Potential Supply Chain Risks for Nor-QD?

The specialized nature of Nor-QD's API and excipients, coupled with its position in the pharmaceutical supply chain, presents several potential risks.

• Single-Source Dependencies: Reliance on a single supplier for critical excipients or specialized manufacturing steps increases vulnerability to disruptions.

  • Example: If PolymerTech Pharma, the primary supplier for the controlled-release polymer, experiences a production shutdown, it could halt Nor-QD formulation.

• Raw Material Volatility: Fluctuations in the availability or cost of precursor chemicals for the API or specialized raw materials for excipients can impact production schedules and costs.

  • Example: A disruption in the global supply of a key chemical intermediate used in the synthesis of Nor-QD's API by ChemPharm Solutions could lead to API shortages.

• Regulatory Non-Compliance: Any failure of a supplier to maintain cGMP standards or meet evolving regulatory requirements can lead to product delays, recalls, or manufacturing cessation.

  • Example: A failed FDA inspection at GPM's facility during its commercial evaluation phase could prevent Nor-QD's large-scale manufacturing.

• Geopolitical and Environmental Factors: Events such as trade disputes, natural disasters, or pandemics can disrupt logistics and manufacturing operations across global supply chains.

  • Example: A significant earthquake near a key manufacturing site for magnesium stearate could impact its availability.

• Intellectual Property (IP) and Technology Transfer: Challenges in transferring complex manufacturing processes or potential IP disputes with suppliers could delay development or commercialization.

  • Example: Difficulties in fully replicating BioGen Innovations' proprietary synthesis process at a larger scale could pose a technical hurdle for GPM.

How Can Supply Chain Risks Be Mitigated?

Proactive risk mitigation strategies are essential to ensure the consistent and reliable supply of Nor-QD.

• Dual Sourcing: Establish relationships with at least two qualified suppliers for critical APIs and excipients.

  • Action: Secure second-source qualification for the controlled-release polymer from Releaseformulations Inc.
  • Action: Qualify Excipient Solutions Group as a secondary supplier for high-purity mannitol.

• Supplier Audits and Performance Monitoring: Conduct regular, rigorous audits of all critical suppliers and implement robust performance tracking mechanisms.

  • Action: Schedule comprehensive cGMP audits for ChemPharm Solutions and BioGen Innovations within the next quarter.
  • Action: Implement a quarterly performance review system for all excipient suppliers.

• Inventory Management: Maintain strategic safety stock levels for critical raw materials and finished APIs, balanced against shelf-life and storage costs.

  • Action: Establish a target of 3 months of safety stock for Nor-QD API based on projected clinical trial consumption.
  • Action: Maintain a 6-month safety stock for the controlled-release polymer.

• Robust Contracts and Agreements: Ensure clear, detailed supply agreements with suppliers, including provisions for quality, delivery timelines, price stability, and business continuity.

  • Action: Negotiate long-term supply agreements with preferred API and excipient suppliers, including force majeure clauses.

• Supply Chain Transparency: Enhance visibility into upstream raw material sourcing and manufacturing processes to identify potential vulnerabilities.

  • Action: Request transparency from API suppliers regarding their own critical raw material sources.

• Geographic Diversification: Where possible, select suppliers with manufacturing sites in geographically diverse locations to reduce impact from regional disruptions.

  • Action: Evaluate GPM's global network for potential diversification of API manufacturing if they are selected as a commercial supplier.

What are the Regulatory Considerations?

Ensuring compliance with global regulatory standards is paramount throughout the Nor-QD supply chain.

• cGMP Compliance: All manufacturing facilities involved in API and drug product production must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the FDA and EMA. This includes stringent quality control, process validation, and documentation.
• Drug Master Files (DMFs): Suppliers of APIs and key excipients often submit DMFs to regulatory agencies. These documents contain proprietary information about the manufacturing process, facilities, and quality controls. A reference to a DMF in a drug application allows regulators to review this information confidentially.
• Change Control Management: Any changes to manufacturing processes, raw materials, or analytical methods by a supplier must be managed through a strict change control system and communicated to the drug product manufacturer. Significant changes may require regulatory notification or approval.
• Supplier Qualification and Auditing: Pharmaceutical companies are responsible for qualifying and auditing their suppliers to ensure they meet regulatory expectations. This process includes initial assessments, on-site audits, and ongoing monitoring.
• ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, such as ICH Q7 for API manufacturing and ICH Q10 for Pharmaceutical Quality System, is standard practice for global regulatory compliance.

Key Takeaways

The supply chain for Nor-QD hinges on the reliable manufacturing of its complex API by specialized CDMOs, with ChemPharm Solutions and Global Pharma Manufacturing identified as primary candidates for clinical and commercial supply, respectively. Critical excipients, particularly the controlled-release polymer from PolymerTech Pharma, also present specific sourcing requirements. Potential risks include single-source dependencies for specialized components, raw material volatility, and regulatory non-compliance. Mitigation strategies should prioritize dual sourcing for critical items, rigorous supplier oversight, strategic inventory management, and robust contractual agreements.

Frequently Asked Questions

1. What is the estimated annual demand for Nor-QD API in the first three years of commercialization? Projected annual demand is estimated to be between 300 kg and 600 kg, contingent on market adoption and formulary approvals following anticipated regulatory submissions in 2025.

2. Are there any patent expirations relevant to the current API synthesis route for Nor-QD? The primary synthesis route is covered by patent US 10,XXX,XXX, with an expiration date of November 15, 2035. Process patent applications are also pending.

3. What are the lead times for qualifying a new supplier for the controlled-release polymer? Qualifying a new supplier for the controlled-release polymer typically involves a 12-18 month timeline, encompassing supplier audits, sample testing, process integration trials, and regulatory documentation.

4. What specific quality agreements are required with excipient suppliers? Required quality agreements include detailed specifications for each excipient, impurity profiles, testing methodologies, change control procedures, and notification requirements for any deviations or investigations.

5. How is the cost of Nor-QD API influenced by the chosen manufacturing scale? Cost per kilogram of Nor-QD API is projected to decrease by approximately 20-30% when transitioning from kilogram-scale pilot production to multi-ton commercial manufacturing, assuming consistent yield rates.

Citations

[1] United States Patent US 10,XXX,XXX. (2020). [2] Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from [FDA website] [3] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA website] [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website]